Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
Forte Biosciences Cash from Operations (Quarterly) : -22.70M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -22.70M |
| March 31, 2026 | -18.81M |
| December 31, 2025 | -16.47M |
| September 30, 2025 | -14.00M |
| June 30, 2025 | -10.06M |
| March 31, 2025 | -10.36M |
| December 31, 2024 | -10.01M |
| September 30, 2024 | -8.133M |
| June 30, 2024 | -5.936M |
| March 31, 2024 | -6.667M |
| December 31, 2023 | -8.969M |
| September 30, 2023 | -9.058M |
| June 30, 2023 | -5.475M |
| March 31, 2023 | -5.204M |
| December 31, 2022 | -2.893M |
| September 30, 2022 | -1.94M |
| June 30, 2022 | -1.377M |
| March 31, 2022 | -1.975M |
| December 31, 2021 | -3.582M |
| September 30, 2021 | -5.127M |
| June 30, 2021 | -3.938M |
| Date | Value |
|---|---|
| March 31, 2021 | -4.03M |
| December 31, 2020 | -3.803M |
| September 30, 2020 | -7.739M |
| June 30, 2020 | -4.016M |
| March 31, 2020 | -2.865M |
| December 31, 2019 | -0.653M |
| September 30, 2019 | -0.553M |
| June 30, 2019 | 16.12M |
| March 31, 2019 | -17.68M |
| December 31, 2018 | -11.94M |
| September 30, 2018 | 0.945M |
| June 30, 2018 | -10.76M |
| March 31, 2018 | -12.71M |
| December 31, 2017 | -9.172M |
| September 30, 2017 | -7.041M |
| June 30, 2017 | -7.353M |
| March 31, 2017 | -7.567M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | -7.785M |
| March 31, 2016 | -6.067M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -147.84M |
| Cash from Financing (Quarterly) | 161.95M |
| Free Cash Flow | -72.03M |
| Free Cash Flow Per Share (Quarterly) | -0.9544 |
| Free Cash Flow to Equity (Quarterly) | -22.70M |
| Free Cash Flow to Firm (Quarterly) | -22.70M |
| Free Cash Flow Yield | -5.17% |